| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/15/2006 | EP1417300B1 Process for the maturation of dentritic cells and a vaccine |
| 03/15/2006 | EP1342730B1 Fusion protein having the enhanced in vivo activity of erythropoietin |
| 03/15/2006 | EP1294893B1 Modification of hepatitis b core antigen |
| 03/15/2006 | EP1294864B1 Mutated furin polypeptides having improved characteristics |
| 03/15/2006 | EP1246905B1 Histone deacetylase-8 proteins, nucleic acids, and methods of use |
| 03/15/2006 | EP1128842B1 Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia |
| 03/15/2006 | EP1121600B1 Method and substances for diagnosis and therapy of sepsis and sepsis-like systemic infections |
| 03/15/2006 | EP1087756A4 Particulate acellular tissue matrix |
| 03/15/2006 | EP1068315B1 Therapeutic agent for ngf |
| 03/15/2006 | EP1001810B1 Pharmaceutical composition with neurotrophic-like biological activity |
| 03/15/2006 | EP0997147B1 Amino acid derivatives |
| 03/15/2006 | EP0942973B1 Mutants of the lag-3 proteins, products for the expression of these mutants and use |
| 03/15/2006 | EP0939590B1 Nucleic acids for use in gene therapy involving intestinal cell gene expression |
| 03/15/2006 | EP0892849B1 Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| 03/15/2006 | EP0870049B1 Complementary adenoviral vector systems and cell lines |
| 03/15/2006 | EP0784477B1 Immunotherapeutic stress protein-peptide complexes against cancer |
| 03/15/2006 | EP0733069B1 Purified primate ctla-8 antigens and related reagents |
| 03/15/2006 | EP0733064B1 Nucleic acids encoding a house dust mite allergen, (der p iii), and uses therefor |
| 03/15/2006 | CN1748026A Characterization of the gsk-3 beta protein and methods of use thereof |
| 03/15/2006 | CN1747966A Peptidic sulfonamides |
| 03/15/2006 | CN1747744A Regeneration and neogenesis of retinal photoreceptor cell using otx2 gene |
| 03/15/2006 | CN1747743A Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases |
| 03/15/2006 | CN1747742A Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis |
| 03/15/2006 | CN1747739A The use of lupin conglutin for the treatment of type ii diabetes |
| 03/15/2006 | CN1747727A Inhibitor for perioperative blood sugar elevation |
| 03/15/2006 | CN1747661A Preparation and food product comprising an active phytase |
| 03/15/2006 | CN1746300A Phosphokinase and use thereof |
| 03/15/2006 | CN1746190A Modified peptides as therapeutic agents |
| 03/15/2006 | CN1746189A Modified peptides as therapeutic agents |
| 03/15/2006 | CN1746188A Analog of GLP-1 |
| 03/15/2006 | CN1746185A Analog of Exendin 4 |
| 03/15/2006 | CN1746184A Trichosanthin mutant and coding gene thereof |
| 03/15/2006 | CN1746182A Design of antisuppository KGD-cyclohepta-peptide, its preparation and use thereof |
| 03/15/2006 | CN1746181A Coronavirus specific T-cellantigen determinate cluster |
| 03/15/2006 | CN1745850A Implant agent for treating ophthalmopathy |
| 03/15/2006 | CN1745847A Medicine composition and method for treating hepatitis with arginase |
| 03/15/2006 | CN1745846A Dental ulcerative glue |
| 03/15/2006 | CN1245520C Method for producing probe arrays for biological materials using fine particles |
| 03/15/2006 | CN1245418C Novel cynthetic antibiotic peptide and its preparing method and use |
| 03/15/2006 | CN1245417C Prodrugs of dipeptidyl peptidase IV inhibitors |
| 03/15/2006 | CN1245216C Stabilized liquid polypeptide-containing. pharmaceutical compositions |
| 03/15/2006 | CN1245215C Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor |
| 03/15/2006 | CN1245214C Oral liquid containing extration of sturgeon and sturgeon active protein capsule, preparation method therefor |
| 03/15/2006 | CN1245213C Microcapsule meterial for durative releasing two factors for restraining new-born blood vessels and its preparing method |
| 03/15/2006 | CN1245212C Cyclosporin A dispersion solid and its preparation method |
| 03/14/2006 | USRE39015 Recombinant polynucleotide or expression vector encoding an antigenic protein, cytokines, antibodies, fusion proteins; open reading frame; isolate host cell; control immune system |
| 03/14/2006 | US7012547 Electronic vehicle toll collection system and method |
| 03/14/2006 | US7012134 Dendritic enriched secreted lymphocyte activation molecule |
| 03/14/2006 | US7012133 Antibodies to C-C chemokine Receptor 3 Protein |
| 03/14/2006 | US7012132 Modified factor VIII |
| 03/14/2006 | US7012130 differential saline precipitation, hydrophobic interaction chromatography, concentration and diafiltration, anionic exchange chromatography, cationic exchange chromatography, concentration and diafiltration, and molecular exclusion chromatography |
| 03/14/2006 | US7012129 Comprises tripeptide amides for inhibiting human immunodeficiency virus infection; solid phase synthesis |
| 03/14/2006 | US7012128 Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays |
| 03/14/2006 | US7012127 site-directed mutagenesis; for prevention and treatment of sepsis and other endotoxin-related disorders |
| 03/14/2006 | US7012100 Cell migration inhibiting compositions and methods and compositions for treating cancer |
| 03/14/2006 | US7012066 for coadministration with interferon and antiviral agent |
| 03/14/2006 | US7012065 Cyclosporins for the treatment of immune disorders |
| 03/14/2006 | US7012064 Cyclosporins for the treatment of immune disorders |
| 03/14/2006 | US7012063 Reducing axon degeneration with proteasome inhibitors |
| 03/14/2006 | US7012062 Use of modified lysozyme C to prepare medicinal compositions for the treatment of some serious diseases |
| 03/14/2006 | US7012060 administering to patient a TNF receptor, the improvement wherein TNF receptor is administered with dehydroepiandrosterone simultaneously, separately or sequentially, so as to achieve an effective blood level of the combination |
| 03/14/2006 | US7011973 recombinant DNA molecules comprising regulatory sequences of an intron of the Vascular Endothelial Growth Factor receptor-2 gene or of a gene homologous to the Flk-1 gene, being capable of conferring expression of a heterologous DNA sequence |
| 03/14/2006 | US7011968 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients |
| 03/14/2006 | US7011965 Compositions and methods for stimulating wound healing and fibroblast proliferation |
| 03/14/2006 | US7011964 Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
| 03/14/2006 | US7011960 Substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acids |
| 03/14/2006 | US7011952 Diagnosis of vision defects; obtain fluid sample, determine autoantibody concentration, amplified concentration indicates vision defects |
| 03/14/2006 | US7011951 Apoptosis-associated gene |
| 03/14/2006 | US7011834 Immunomodulating dimers |
| 03/14/2006 | US7011833 Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent |
| 03/14/2006 | US7011831 Recombinant α-galactosidase A therapy for Fabry disease |
| 03/14/2006 | US7011826 Control of acidosis |
| 03/14/2006 | US7011825 Erythropoietin solution preparation |
| 03/14/2006 | CA2324348C Methods and compositions for peptide synthesis |
| 03/14/2006 | CA2267879C Heteroaryl succinamides and their use as metalloproteinase inhibitors |
| 03/14/2006 | CA2141300C Assessment of vitamin d receptors allelic variation |
| 03/14/2006 | CA1341501C Vectors for the expression and segregation of hirudine by transformed yeasts |
| 03/10/2006 | CA2518650A1 Clostridium botulinum toxin formulation and method for reducing weight |
| 03/09/2006 | WO2006026785A2 COMPOSITIONS AND METHODS FOR MODULATING PGC-1α TO TREAT NEUROLOGICAL DISEASES AND DISORDERS |
| 03/09/2006 | WO2006026739A2 Methods to enhance hemodynamic stability using oxygen carrying compositions |
| 03/09/2006 | WO2006026713A2 Topical benfotiamine and pyridoxamine compositions |
| 03/09/2006 | WO2006026678A2 Method for downregulating an immune reaction |
| 03/09/2006 | WO2006026663A1 Methods for treating congestive heart failure |
| 03/09/2006 | WO2006026570A2 Use of stem cells to generate inner ear cells |
| 03/09/2006 | WO2006026536A2 Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp) |
| 03/09/2006 | WO2006026524A2 Werner's syndrome helicase as a target for anti-hiv/aids therapy |
| 03/09/2006 | WO2006026496A2 Immunosuppressive ningalin compounds |
| 03/09/2006 | WO2006026426A2 Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally |
| 03/09/2006 | WO2006026355A2 Relaxin-chimeric polypeptides and their preparation and use |
| 03/09/2006 | WO2006026352A1 Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
| 03/09/2006 | WO2006026348A1 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| 03/09/2006 | WO2006026304A1 Cardioprotective formulations and uses thereof |
| 03/09/2006 | WO2006026299A1 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b and other therapeutic proteins |
| 03/09/2006 | WO2006025995A2 Compositions and methods using md-2 mutants and chimeric proteins |
| 03/09/2006 | WO2006025978A2 Non-antibiotic intervention of chlamydial infection |
| 03/09/2006 | WO2006025976A1 Methods for treating cancer |
| 03/09/2006 | WO2006025882A2 Absorption enhancers for drug administration |
| 03/09/2006 | WO2006025536A1 Anti-sars virus agent |
| 03/09/2006 | WO2006025448A1 Method of protecging digestive organ with the use of thioredoxin |
| 03/09/2006 | WO2006025425A1 Protein participating in inhibition of plasmodium growth |